Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters

L'Hospitalet de Llobregat-Barcelona, Spain Clinical Trials

A listing of L'Hospitalet de Llobregat-Barcelona, Spain clinical trials actively recruiting patients volunteers.

RESULTS

Found (26) clinical trials

E6/E7 mRNA Performance to Detect HSIL and Cost-effectiveness Analysis of This Screening Strategy in HIV + MSM

Introduction: Anal cancer incidence is increasing in HIV-infected men who have sex with men (MSM). There are still no standardized criteria for anal cancer screening. Anal cytology has not shown enough sensitivity and specificity in the selection of patients who need more invasive procedures, as high resolution anoscopy (HRA). Human ...

Phase N/A

1.34 miles

Learn More »

PROSABI: Prospective Multi-centre Study of Prognostic Factors in CRPC Patients Treated With Abiraterone Acetate.

This is a non-interventional prospective study in metastatic CRPC designed to explore biomarkers, composed by patients treated with Abiraterone Acetate. Key inclusion criteria: a) histological confirmation of prostate cancer; b) documented criteria (PCWG2) for CRPC; c) availability of tumour tissue; d) candidate for standard treatment with Abiraterone Acetate. Primary end ...

Phase N/A

1.34 miles

Learn More »

PROSTAC: Prospective Multi-centre Study of Prognostic Factors in CRPC Patients Treated With Docetaxel or Cabazitaxel.

This is a non-interventional prospective study in metastatic CRPC designed to explore biomarkers, composed by two cohorts of patients treated with docetaxel or cabazitaxel. Key inclusion criteria: a) histological confirmation of prostate cancer; b) documented criteria (PCWG2) for CRPC; c) availability of tumour tissue; d) candidate for standard treatment with ...

Phase N/A

1.34 miles

Learn More »

PROSENZA: Prospective Multi-Centre Study of Prognostic Factors in CRPC Patients Treated With Enzalutamide.

This is a non-interventional prospective study in metastatic CRPC designed to explore biomarkers, composed by patients treated with Enzalutamide. Key inclusion criteria: a) histological confirmation of prostate cancer; b) documented criteria (PCWG2) for CRPC; c) availability of tumour tissue; d) candidate for standard treatment with enzalutamide. Primary end point: to ...

Phase N/A

1.34 miles

Learn More »

Dose Escalation and Dose Expansion Study of GSK525762 in Combination With Androgen Deprivation Therapy and Other Agents in Subjects With Castrate-resistant Prostate Cancer

The study aims to evaluate the combination of GSK525762 with other agents that have been shown to be effective in the treatment of CRPC or metastatic CRPC, including approved agents (e.g., abiraterone, enzalutamide) as well as investigational agents for mCRPC that have proven to show efficacy and can be combined ...

Phase

1.5 miles

Learn More »

Clinical Study to Evaluate the Efficacy and Safety of Givinostat in Ambulant Patients With Duchenne Muscular Dystrophy

Givinostat or placebo oral suspension (10 mg/mL) will be administered orally as 2 oral doses daily while the subject is in fed state, according to the child's weight. Study drug should be permanently stopped if any of the following occur: severe drug-related diarrhoea; any drug-related Serious Adverse Event; QTcF >500 ...

Phase

1.53 miles

Learn More »

A Phase III Double-blind Study With Idebenone in Patients With Duchenne Muscular Dystrophy (DMD) Taking Glucocorticoid Steroids

The SIDEROS trial is a randomized, placebo controlled, parallel group study of the efficacy of idebenone in delaying the loss of respiratory function, whilst also monitoring safety and tolerability of idebenone in at least 266 DMD patients taking stable dose of concomitant glucocorticoid steroids. The study treatment period will be ...

Phase

1.53 miles

Learn More »

Safety and Efficacy of Nonacog Beta Pegol (N9-GP) in Previously Untreated Patients With Haemophilia B

This trial is conducted globally. The aim of the trial is to investigate the safety and efficacy of nonacog beta pegol (N9-GP) in previously untreated patients with Haemophilia B.

Phase

1.53 miles

Learn More »

BAY81-8973 Pediatric Safety and Efficacy Trial

The objective of the study is to demonstrate the safety and efficacy of treatment with BAY81-8973 for prophylaxis and breakthrough bleeds in children with severe haemophilia A.

Phase

1.53 miles

Learn More »

A Study to Evaluate Efficacy of rFVIIIFc for Immune Tolerance Induction (ITI) in Severe Hemophilia A Participants With Inhibitors Undergoing the First ITI Treatment (verITI-8 Study)

The primary purpose of this study is to describe the time to tolerization (i.e., ITI success) with rFVIIIFc in participants within a maximum of 48 weeks (12 months) of ITI treatment.

Phase

1.54 miles

Learn More »